Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC
Cancer · 2024
DOI: 10.1002/cncr.35529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 2 Literaturangaben.
Abstract (Originalsprache)
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, durvalumab remains inaccessible to many patients for whom it is indicated as a standard of care after chemoradiation. In addition, a study assesses a fixed‐duration combination regimen of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia, and multitargeted therapy is safe and leads to durable remission of diffuse large B‐cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Nierengarten, M. B. (2024). Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC. Cancer. https://doi.org/10.1002/cncr.35529
Vancouver
Nierengarten MB. Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC. Cancer. 2024. doi:10.1002/cncr.35529
BibTeX
@article{Nierengarten2024,
author = {Nierengarten, Mary Beth},
title = {Durvalumab not cost‐effective with current pricing strategies for stage III NSCLC},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35529}
}
EUVIMED